OncologyConsults




Breast CME
CME Activities

Novel Combination Therapies in HR+/HER2- Metastatic Breast Cancer: New Standards of Care? CME Credits: 1
Historically, the cornerstone of the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer has been endocrine therapy. Unfortunately, the development of endocrine resistance can limit the efficacy of this approach.
Faculty: Karen Lisa Smith, MD, MPH, and Maria Raquel Nunes, MD Expires: 7/30/2019


The Emerging Role of Immunotherapy in Treating Patients with Triple-Negative Breast Cancer CME Credits: 0.5
While the introduction of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit.
Faculty: Leisha A. Emens, MD, PhD Expires: 3/12/2019